Long-term safety study of RGL-193 for Parkinson's disease

This study tests an experimental treatment (LY3962681) for people with early Parkinson's. It aims to see if the treatment is safe and can slow the disease. You must have a confirmed diagnosis, be in good overall health, and have stable medication use.

This study follows patients who previously received IPS101A, an experimental gene therapy treatment for severe Parkinson's disease. Researchers want to check how you're doing over time and gather information about the treatment's long-term effects.

This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.

This study tests an experimental vaccine called TRB-001 in people with Parkinson's disease who have already received a previous immunotherapy targeting alpha-synuclein. The goal is to see if the vaccine is safe and how it affects the immune system and the disease.

This trial tests a new injection called UX-DA003 for people with Parkinson's disease whose current medications are becoming less effective. It aims to see if this treatment can help reduce "off" time and improve motor symptoms.

This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.